ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $85.44 million. The enterprise value is -$45.77 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ALXO has 52.74 million shares outstanding. The number of shares has increased by 24.48% in one year.
Current Share Class | 52.74M |
Shares Outstanding | 52.74M |
Shares Change (YoY) | +24.48% |
Shares Change (QoQ) | +1.66% |
Owned by Insiders (%) | 2.14% |
Owned by Institutions (%) | 49.21% |
Float | 35.13M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.62 |
P/TBV Ratio | 0.62 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.13.
Current Ratio | 4.82 |
Quick Ratio | 4.63 |
Debt / Equity | 0.13 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -93.11 |
Financial Efficiency
Return on equity (ROE) is -98.94% and return on invested capital (ROIC) is -59.14%.
Return on Equity (ROE) | -98.94% |
Return on Assets (ROA) | -49.24% |
Return on Capital (ROIC) | -59.14% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.10M |
Employee Count | 72 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.42% in the last 52 weeks. The beta is 1.04, so ALXO's price volatility has been similar to the market average.
Beta (5Y) | 1.04 |
52-Week Price Change | -88.42% |
50-Day Moving Average | 1.49 |
200-Day Moving Average | 6.40 |
Relative Strength Index (RSI) | 52.09 |
Average Volume (20 Days) | 1,376,031 |
Short Selling Information
The latest short interest is 7.17 million, so 13.60% of the outstanding shares have been sold short.
Short Interest | 7.17M |
Short Previous Month | 7.23M |
Short % of Shares Out | 13.60% |
Short % of Float | 20.42% |
Short Ratio (days to cover) | 8.58 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -159.88M |
Pretax Income | -166.20M |
Net Income | -151.16M |
EBITDA | -159.01M |
EBIT | -159.88M |
Earnings Per Share (EPS) | -$2.97 |
Full Income Statement Balance Sheet
The company has $148.57 million in cash and $17.36 million in debt, giving a net cash position of $131.22 million or $2.49 per share.
Cash & Cash Equivalents | 148.57M |
Total Debt | 17.36M |
Net Cash | 131.22M |
Net Cash Per Share | $2.49 |
Equity (Book Value) | 136.81M |
Book Value Per Share | 2.59 |
Working Capital | 123.56M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$129.54 million and capital expenditures -$535,000, giving a free cash flow of -$130.08 million.
Operating Cash Flow | -129.54M |
Capital Expenditures | -535,000 |
Free Cash Flow | -130.08M |
FCF Per Share | -$2.47 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |